Investors in Shenzhen Neptunus Bioengineering (SZSE:000078) From Five Years Ago Are Still Down 42%, Even After 5.3% Gain This Past Week
Investors in Shenzhen Neptunus Bioengineering (SZSE:000078) From Five Years Ago Are Still Down 42%, Even After 5.3% Gain This Past Week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) shareholders for doubting their decision to hold, with the stock down 42% over a half decade. But it's up 5.3% in the last week. Less than a week ago Shenzhen Neptunus Bioengineering announced its financial results; you can catch up on the most recent data by reading our company report.
為了證明挑選個股的努力是合理的,值得努力超越市場指數基金的回報。但幾乎可以肯定的是,每個投資者都會同時擁有表現優異和表現不佳的股票。所以我們不會責怪長期深圳市海王星生物工程有限公司。(SZSE:000078)股東對他們持有股票的決定表示懷疑,該股在過去五年中下跌了42%。但最近一週上漲了5.3%。不到一週前,深圳海王星生物工程公司公佈了財務業績;您可以通過閱讀我們的公司報告來了解最新的數據。
Although the past week has been more reassuring for shareholders, they're still in the red over the last five years, so let's see if the underlying business has been responsible for the decline.
儘管過去一週對股東來說更令人安心,但他們在過去五年仍處於虧損狀態,所以讓我們看看基礎業務是否對股價下跌負有責任。
View our latest analysis for Shenzhen Neptunus Bioengineering
查看我們對深圳海王星生物工程的最新分析
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
在他的文章中格雷厄姆和多德斯維爾的超級投資者沃倫·巴菲特描述了股價並不總是理性地反映一家企業的價值。一種不完美但簡單的方法來考慮市場對一家公司的看法是如何改變的,那就是將每股收益(EPS)的變化與股價走勢進行比較。
In the last half decade Shenzhen Neptunus Bioengineering saw its share price fall as its EPS declined below zero. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.
在過去的五年裡,深圳海王星生物工程的股價下跌,每股收益降至零以下。由於該公司已陷入虧損狀態,很難將每股收益的變化與股價的變化進行比較。然而,我們可以說,在這種情況下,我們預計會看到股價下跌。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下圖顯示了EPS是如何隨著時間的推移進行跟蹤的(如果您點擊該圖像,您可以看到更多詳細資訊)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/pic/0-b47f91155630b8ee116c6228cda58447-0-3b3accbf790cba07b2eef4f3edcf0360.png/big)
Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.
在買賣股票之前,我們總是建議仔細研究一下歷史增長趨勢,可以在這裡找到。
A Different Perspective
不同的視角
Shenzhen Neptunus Bioengineering shareholders gained a total return of 5.0% during the year. But that return falls short of the market. On the bright side, that's still a gain, and it is certainly better than the yearly loss of about 7% endured over half a decade. It could well be that the business is stabilizing. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Shenzhen Neptunus Bioengineering is showing 2 warning signs in our investment analysis , you should know about...
深圳海王星生物工程股東年內總回報達5.0%。但這一回報率低於市場。從好的方面來看,這仍然是一種收益,而且肯定比五年來每年約7%的損失要好。這很可能是因為業務正在企穩。我發現,把股價作為衡量企業業績的長期指標是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他資訊。即便如此,請注意深圳海王星生物工程公司正在展示我們的投資分析中的2個警告信號,你應該知道關於……
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).
如果你喜歡和管理層一起買股票,那麼你可能會喜歡這本書免費公司名單。(提示:內部人士一直在買入這些股票)。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。